Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
Xiantong ZouYibing LuZewei ShenPing HuWenyan LiuQiu ZhangBimin ShiPublished in: Diabetes, obesity & metabolism (2024)
These results support the effectiveness of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg across a broad range of baseline characteristics, in participants with T2D from SUSTAIN China.
Keyphrases